INDICATIONS AND USAGE
KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane,separately or in combination.
DOSAGE FORMS & STRENGTHS
Lyophilized powder in single-use vials containing 100 mg per vial or 160 mg per vial.
Manufactured By: Genentech
Prescribing Information URL: Click Here
FDA approved Anti-Cancer medicine KADCYLA (ado-trastuzumab emtansine) for injection. FDA-Approved is available upon request. To get best retail price of KADCYLA (ado-trastuzumab emtansine) for injection. FDA-Approved in India, For emergency product orders call 8750295029 (Mr. Neeraj Nagpal) or For enquires email [email protected] For advanced treatments in India, Medvitaz Pharma Solution can even help patient to discuss with Medical Oncologist.
Trastuzumab emtansine also known as ado-trastuzumab emtansine and sold under the trade name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1.
In the United States, ado-trastuzumab emtansine was approved specifically for treatment of HER2-positive metastatic breast cancer (mBC) in patients who have been treated previously with trastuzumab and a taxane (paclitaxel or docetaxel), and who have already been treated for mBC or developed tumor recurrence within six months of adjuvant therapy.
Approval was based on the EMILIA study, a phase III clinical trial that compared trastuzumab emtansine versus capecitabine (Xeloda) plus lapatinib (Tykerb) in 991 people with unresectable, locally advanced or metastatic HER2-positive breast cancer who had previously been treated with trastuzumab and taxane chemotherapy. This trial showed improved progression-free survival in patients treated with trastuzumab emtansine (median 9.6 vs. 6.4 months), along with improved overall survival (median 30.9 vs. 25.1 months) and safety.
You can order ado-trastuzumab emtansine for injection through Medvitaz Pharma Solutions under Named Patient Program (NPP). Medvitaz provides patients and physicians access to commercialy approved medicines that are not available to them in their own country. Medvitaz objectives is to make quality medicines available at affordable prices for patients and physicians. To get best retail price/cost of ado-trastuzumab emtansine for injection in India, Call 8750295029 or Email [email protected]. FDA approved drugs of Australia, Canada, Delhi, EU, India, New Zealand, Singapore, Switzerland, Turkey & USA.
Head of Operations
The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.
Contact us and we will reply as soon as possible!
MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.
